BTBD7

Across TCGA pan-cancer cohorts, BTBD7 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of BTBD7’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where BTBD7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BTBD7 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRP, HNSC, and THCA are the cancer types where BTBD7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTBD7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+0.816	<.001	11	view →
HNSC	All	All	+0.535	<.001	9	view →
THCA	Male	All	−0.685	<.001	8	view →
LIHC	Female	II,III,IV	+0.885	<.001	7	view →
BRCA	Female	All	−0.281	<.001	6	view →
CHOL	Male	All	+2.056	<.001	5	view →
KICH	All	All	−0.740	<.001	5	view →
COAD	All	All	−0.347	<.001	5	view →
KIRC	Male	III,IV	−0.404	.021	4	view →
LUSC	All	All	+0.257	.007	4	view →
READ	All	All	−0.518	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

BTBD7–KIRP

Open the KIRP breakdown →